Highlights Newsletter 1
This newsletter presents you the following key sessions:
1. Podcast with Dr. Ahmed about real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle
cell lymphoma
2. Benefit of ide-cel versus standard regimens maintained across patient populations with high-risk
relapsed/refractory multiple myeloma
3. Imetelstat effective in heavily transfusion-dependent patients with lower-risk myelodysplastic syndrome
4. Crovalimab non-inferior to eculizumab in patients with paroxysmal nocturnal haemoglobinuria naïve to
complement inhibitors
5. Epcoritamab with rituximab plus lenalidomide provides durable responses in patients with high-risk follicular
lymphoma, regardless of POD24 status